RxDoctor Payments Data

Tri Nguyen, MD

Cardiovascular Disease · San Diego, CANPI 1962598425

Payments from drug & device makers

$522in general payments, 2019–2025

Across 12 payments — averaging $43.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$138
  • LEO Pharma Inc.$125
  • Atricure, Inc.$100
  • Novartis$37
  • Boehringer Ingelheim$32
  • Johnson & Johnson$28
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$49795%
  • Education$245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,343
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin193$164,133
EliquisApixaban95$78,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$42,774
ProliaDenosumab19$30,710
JanuviaSitagliptin Phosphate21$19,209
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,169
EntrestoSacubitril/Valsartan11$15,296
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp43$11,118
Solifenacin Succinate40$8,898
Rosuvastatin Calcium337$8,042
TradjentaLinagliptin14$6,920
Cyclosporine16$6,441
Atorvastatin Calcium366$5,834
Metoprolol Succinate196$5,646
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$5,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$32$171,053207 claims
GSKTrelegy Ellipta$16$42,77442 claims
AstraZenecaBreztri Aerosphere$11$18,16922 claims
NovartisEntresto$37$15,29611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →